00:29 , May 19, 2015 |  BC Extra  |  Company News

Management tracks

Endocrine company Chiasma Inc. (Jerusalem, Israel) hired Mark Fitzpatrick as CFO, effective June 10. Fitzpatrick was CFO of rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), where Chief Accounting Officer David Aubuchon will succeed him as...
07:00 , May 18, 2015 |  BC Week In Review  |  Company News

Calchan neurology news

Calchan transitioned from a virtual company and added Brenda Reynolds as CEO, Manjit Rahelu as COO and Zahid Ali as CSO. Reynolds and Rahelu had been with Convergence Pharmaceuticals Ltd. , which Biogen Inc. (NASDAQ:BIIB,...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

CNV2197944: Phase II started

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a double-blind, placebo-controlled, crossover, Hungarian Phase II trial to evaluate 75 mg oral CNV2197944 thrice daily for 3 weeks in about 165 DPN patients. As part of its restructuring...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

CNV2197944: Phase II started

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a double-blind, placebo-controlled Phase II trial to evaluate repeat doses of oral CNV2197944. As part of its restructuring in 2011, Convergence transferred rights to CNV2197944 to Calchan. Convergence is...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

CNV2197944: Phase I data

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) reported data from a placebo-controlled, U.K. Phase I trial in healthy volunteers showing that multiple ascending-doses of oral CNV2197944 were well tolerated with few adverse events reported at doses that...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

CNV2197944: Phase I started

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a placebo-controlled, U.K. Phase I trial to evaluate multiple ascending-doses of oral CNV2197944 for 28 days in about 50 healthy volunteers. Convergence is developing CNV2197944 on behalf of Calchan,...